Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 17;10(5):1393-1403.
doi: 10.1016/j.ekir.2025.02.007. eCollection 2025 May.

Longitudinal Lipid Trajectories and Progression of CKD in Children

Affiliations

Longitudinal Lipid Trajectories and Progression of CKD in Children

Uwe Querfeld et al. Kidney Int Rep. .

Abstract

Introduction: There are discrepant findings regarding the effect of dyslipidemia on disease progression in adult patients with chronic kidney disease (CKD).

Methods: In a prospective cohort study of children with stage 3 to 5 (predialysis) CKD, triglycerides (TGs), total cholesterol (CHOL), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were measured semiannually. We investigated whether CKD progression is associated with serum lipid levels at baseline and with lipid trajectories during follow-up. CKD progression was defined as the time to a composite event of 50% reduction in estimated glomerular filtration rate (eGFR), eGFR < 10 ml/min per 1.73 m2, or start of kidney replacement therapy. By semiparametric group-based trajectory modeling (GBTM), 2 trajectories were defined for each lipid, termed "high" and "low."

Results: A total of 681 patients aged 12.2 ± 3.3 years with a mean eGFR of 26.9 ± 11.6 ml/min per 1.73 m2 were included. Kidney diagnosis was classified as congenital anomalies of the kidneys and urinary tracts (CAKUT) in 69%, glomerulopathy in 8.4%, and other disorders in 22.6% of patients. During a median of 5.1 years of follow-up, 59% of patients reached the composite end point. Kidney survival was significantly different for HDL-C (P = 0.0128), but not for other lipid trajectories in the Kaplan-Meier analysis. There was no significant association of any of the lipid trajectories with CKD progression in Cox proportional hazard models. Variables consistently associated with CKD progression in models for each lipid at baseline and for lipid trajectories included age, a diagnosis other than CAKUT, eGFR at baseline, albuminuria, the serum albumin level, and diastolic blood pressure (BP).

Conclusions: These data do not support an important role for lipids in the progression of CKD in children.

Keywords: children; chronic kidney disease; dyslipidemia; progression; proteinuria.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1
Figure 1
Averaged estimated (solid line) and observed (points) trajectories for each lipid. Trajectories were defined by GBTM. Classification into 2 trajectory groups with consistently high (red) versus low (blue) serum lipid levels during follow-up. Straight grey lines indicate age-related cutoffs for high and low serum levels for cholesterol and LDL-cholesterol, low levels of HDL-cholesterol and high levels of triglycerides, respectively. GBTM, group-based trajectory modeling, HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Figure 2
Figure 2
Kaplan-Maier plots of kidney survival for longitudinal serum lipid trajectories. Kidney survival was defined as the time to a composite event of 50% reduction in eGFR, eGFR <10 ml/min per 1.73 m2 or start of kidney replacement therapy (KRT), whichever occurred first. eGFR, estimated glomerular filtration rate.

References

    1. Vaziri N.D. Dyslipidemia of chronic renal failure: The nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol. 2006;290:F262–F272. doi: 10.1152/ajprenal.00099.2005. - DOI - PubMed
    1. Kaysen G.A., Don B., Schambelan M. Proteinuria, albumin synthesis and hyperlipidaemia in the nephrotic syndrome. Nephrol Dial Transplant. 1991;6:141–149. doi: 10.1093/ndt/6.2.141. - DOI - PubMed
    1. Khurana M., Silverstein D.M. Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease. Pediatr Nephrol. 2015;30:2073–2084. doi: 10.1007/s00467-015-3075-9. - DOI - PubMed
    1. Moradi H., Vaziri N.D. Molecular mechanisms of disorders of lipid metabolism in chronic kidney disease. Front Biosci (Landmark Ed) 2018;23:146–161. doi: 10.2741/4585. - DOI - PubMed
    1. Saland J.M., Pierce C.B., Mitsnefes M.M., et al. Dyslipidemia in children with chronic kidney disease. Kidney Int. 2010;78:1154–1163. doi: 10.1038/ki.2010.311. - DOI - PMC - PubMed

LinkOut - more resources